Spinogenix, the company behind the once-a-day pill that restored lost nerve cell connections in people with amyotrophic lateral sclerosis (ALS), has now set its sights on using the pill to provide a novel treatment for another debilitating disease: schizophrenia. Earlier this year, on a groundbreaking once-a-day pill that restored lost nerve cell connections or synapses in the brain. The creation of biopharmaceutical company , early clinical trials of the drug, called SPG302, to treat the fatal nervous system disease amyotrophic lateral sclerosis (ALS) yielded impressive results.
Now, Spinogenix is again about to embark on a clinical trial of SPG302, this time to evaluate its effectiveness in treating another serious and debilitating disease: schizophrenia. “We are excited to advance the first clinical therapy capable of reversing synapse loss in schizophrenia, which may provide a much-needed advancement in the treatment of multiple symptoms and patients who are treatment resistant,” said Dr. Stella Sarraf, Spinogenix’s CEO and founder.
is a serious, chronic mental illness that affects how people think, feel, and perceive. Its hallmark is psychosis, which describes when a person is disconnected from reality. Schizophrenia also presents with ‘positive symptoms’ like hallucinations, delusions, and disorganized speech, ‘ ’ like social withdrawal, an inability to feel pleasure (anhedonia), apathy, and lack of emotions, and cognitive symptoms such as problems with me.